Studies have shown promising results with the early combination of everolimus and sorafenib in liver transplantation for HCC, confirming the potential of mTOR inhibitors (mTORi) for improving patient outcomes [15, 16]. This evidence concerns the gene MTOR and hepatocellular carcinoma.